vs
Side-by-side financial comparison of AMBARELLA INC (AMBA) and TransMedics Group, Inc. (TMDX). Click either name above to swap in a different company.
TransMedics Group, Inc. is the larger business by last-quarter revenue ($160.8M vs $108.5M, roughly 1.5× AMBARELLA INC). TransMedics Group, Inc. runs the higher net margin — 65.6% vs -13.9%, a 79.5% gap on every dollar of revenue. On growth, TransMedics Group, Inc. posted the faster year-over-year revenue change (32.2% vs 31.2%). AMBARELLA INC produced more free cash flow last quarter ($31.4M vs $19.0M). Over the past eight quarters, AMBARELLA INC's revenue compounded faster (45.0% CAGR vs 28.8%).
Ambarella, Inc. is an American fabless semiconductor design company, focusing on low-power, high-definition (HD) and Ultra HD video compression, image processing, and computer vision processors. Ambarella's products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver and in-cabin monitoring, autonomous driving, and robotics applications. Ambarella's system on chips ...
TransMedics Group, Inc. develops and commercializes innovative medical technologies for organ transplantation. Its flagship Organ Care System keeps donor organs viable during transport, improving transplant outcomes for heart, lung, liver and kidney recipients. It serves transplant centers and organ procurement organizations across North America, Europe and Asia-Pacific.
AMBA vs TMDX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $108.5M | $160.8M |
| Net Profit | $-15.1M | $105.4M |
| Gross Margin | 59.6% | 58.1% |
| Operating Margin | -15.0% | 13.2% |
| Net Margin | -13.9% | 65.6% |
| Revenue YoY | 31.2% | 32.2% |
| Net Profit YoY | 37.2% | 1436.9% |
| EPS (diluted) | $-0.35 | $2.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $108.5M | $160.8M | ||
| Q3 25 | $95.5M | $143.8M | ||
| Q2 25 | $85.9M | $157.4M | ||
| Q1 25 | $84.0M | $143.5M | ||
| Q4 24 | $82.7M | $121.6M | ||
| Q3 24 | $63.7M | $108.8M | ||
| Q2 24 | $54.5M | $114.3M | ||
| Q1 24 | $51.6M | $96.8M |
| Q4 25 | $-15.1M | $105.4M | ||
| Q3 25 | $-20.0M | $24.3M | ||
| Q2 25 | $-24.3M | $34.9M | ||
| Q1 25 | $-20.2M | $25.7M | ||
| Q4 24 | $-24.1M | $6.9M | ||
| Q3 24 | $-34.9M | $4.2M | ||
| Q2 24 | $-37.9M | $12.2M | ||
| Q1 24 | $-60.6M | $12.2M |
| Q4 25 | 59.6% | 58.1% | ||
| Q3 25 | 58.9% | 58.8% | ||
| Q2 25 | 60.0% | 61.4% | ||
| Q1 25 | 60.0% | 61.5% | ||
| Q4 24 | 60.6% | 59.2% | ||
| Q3 24 | 60.8% | 55.9% | ||
| Q2 24 | 60.9% | 60.6% | ||
| Q1 24 | 59.8% | 61.9% |
| Q4 25 | -15.0% | 13.2% | ||
| Q3 25 | -23.0% | 16.2% | ||
| Q2 25 | -30.1% | 23.2% | ||
| Q1 25 | -30.2% | 19.1% | ||
| Q4 24 | -30.9% | 7.1% | ||
| Q3 24 | -56.9% | 3.6% | ||
| Q2 24 | -72.4% | 10.9% | ||
| Q1 24 | -80.8% | 12.8% |
| Q4 25 | -13.9% | 65.6% | ||
| Q3 25 | -20.9% | 16.9% | ||
| Q2 25 | -28.3% | 22.2% | ||
| Q1 25 | -24.1% | 17.9% | ||
| Q4 24 | -29.1% | 5.6% | ||
| Q3 24 | -54.8% | 3.9% | ||
| Q2 24 | -69.6% | 10.7% | ||
| Q1 24 | -117.4% | 12.6% |
| Q4 25 | $-0.35 | $2.59 | ||
| Q3 25 | $-0.47 | $0.66 | ||
| Q2 25 | $-0.58 | $0.92 | ||
| Q1 25 | $-0.48 | $0.70 | ||
| Q4 24 | $-0.58 | $0.19 | ||
| Q3 24 | $-0.85 | $0.12 | ||
| Q2 24 | $-0.93 | $0.35 | ||
| Q1 24 | $-1.51 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $174.1M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $590.1M | $473.1M |
| Total Assets | $751.9M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $174.1M | — | ||
| Q3 25 | $142.7M | — | ||
| Q2 25 | $141.3M | — | ||
| Q1 25 | $144.6M | — | ||
| Q4 24 | $127.1M | — | ||
| Q3 24 | $153.9M | $330.1M | ||
| Q2 24 | $131.8M | $362.8M | ||
| Q1 24 | $144.9M | $350.2M |
| Q4 25 | $590.1M | $473.1M | ||
| Q3 25 | $576.5M | $355.2M | ||
| Q2 25 | $572.7M | $318.1M | ||
| Q1 25 | $561.4M | $266.3M | ||
| Q4 24 | $554.3M | $228.6M | ||
| Q3 24 | $547.6M | $209.9M | ||
| Q2 24 | $555.4M | $189.9M | ||
| Q1 24 | $559.9M | $159.5M |
| Q4 25 | $751.9M | $1.1B | ||
| Q3 25 | $706.4M | $946.0M | ||
| Q2 25 | $701.9M | $890.5M | ||
| Q1 25 | $689.0M | $837.5M | ||
| Q4 24 | $670.8M | $804.1M | ||
| Q3 24 | $650.3M | $785.6M | ||
| Q2 24 | $638.7M | $758.6M | ||
| Q1 24 | $657.7M | $723.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.3M | $34.5M |
| Free Cash FlowOCF − Capex | $31.4M | $19.0M |
| FCF MarginFCF / Revenue | 29.0% | 11.8% |
| Capex IntensityCapex / Revenue | 2.7% | 9.7% |
| Cash ConversionOCF / Net Profit | — | 0.33× |
| TTM Free Cash FlowTrailing 4 quarters | $64.3M | $133.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.3M | $34.5M | ||
| Q3 25 | $5.5M | $69.6M | ||
| Q2 25 | $14.8M | $91.6M | ||
| Q1 25 | $25.4M | $-2.9M | ||
| Q4 24 | $6.6M | $19.7M | ||
| Q3 24 | $16.7M | $6.9M | ||
| Q2 24 | $-15.0M | $25.7M | ||
| Q1 24 | $-4.0M | $-3.4M |
| Q4 25 | $31.4M | $19.0M | ||
| Q3 25 | $1.4M | $61.9M | ||
| Q2 25 | $10.2M | $82.5M | ||
| Q1 25 | $21.2M | $-29.9M | ||
| Q4 24 | $4.1M | $6.1M | ||
| Q3 24 | $14.2M | $-41.3M | ||
| Q2 24 | $-16.1M | $2.0M | ||
| Q1 24 | $-6.0M | $-47.6M |
| Q4 25 | 29.0% | 11.8% | ||
| Q3 25 | 1.4% | 43.1% | ||
| Q2 25 | 11.9% | 52.4% | ||
| Q1 25 | 25.3% | -20.8% | ||
| Q4 24 | 5.0% | 5.0% | ||
| Q3 24 | 22.2% | -38.0% | ||
| Q2 24 | -29.5% | 1.7% | ||
| Q1 24 | -11.6% | -49.2% |
| Q4 25 | 2.7% | 9.7% | ||
| Q3 25 | 4.3% | 5.3% | ||
| Q2 25 | 5.3% | 5.8% | ||
| Q1 25 | 5.0% | 18.8% | ||
| Q4 24 | 3.0% | 11.2% | ||
| Q3 24 | 4.0% | 44.3% | ||
| Q2 24 | 2.1% | 20.8% | ||
| Q1 24 | 3.7% | 45.6% |
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | 2.86× | ||
| Q2 25 | — | 2.62× | ||
| Q1 25 | — | -0.11× | ||
| Q4 24 | — | 2.87× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | — | -0.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMBA
| TW | $76.0M | 70% |
| Asia Pacific Other Than Taiwan | $20.2M | 19% |
| North America Other Than United States | $7.4M | 7% |
| Other | $5.0M | 5% |
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
